Eccogene Raises CNY 180 Million in Series B Equity Financing for Treatments of Metabolic Diseases

Clinical-stage biotech company Eccogene has raised CNY180m ($25m) in series B equity financing to support the development of its clinical-stage pipeline. The funding round was led by New Alliance Capital and Zhangjiang Healthcare Venture Capital, and included new investors Rockbleu Capital, YuFu Investment, Huajin Capital and Elikon Venture, as well as existing backers Delos Capital, Oriza Seed ..